Elizabeth A Brem

Elizabeth A Brem, MD, is an Assistant Professor in the Division of Hematology and Oncology at the University of California, Irvine (UCI) School of Medicine. Her research focuses on lymphoma subtypes, particularly diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL), with expertise in treatment outcomes for older patients and those with comorbidities.

• UCI School of Medicine, Department of Medicine
• Division of Hematology and Oncology

Dr. Brem's work emphasizes geriatric assessments, chemotherapy protocols, and novel treatment modalities like Bruton's Tyrosine Kinase inhibitors (BTKi). She leads clinical trial S1918 and has consulted for Genentech, AstraZeneca, and ADC Therapeutics.

Her 2024 publication on blastoid variant MCL highlights poor outcomes with chemo-immunotherapy and the potential of BTKi-based treatments. Recent studies analyze chemoradiotherapy vs. chemotherapy in sinonasal DLBCL, showing improved survival with combined approaches.

Scientific contributions include:

• Principal Investigator for S1918
• Advisory Board, ADC Therapeutics
• Speaker, AstraZeneca and BeiGene
• Consultant, Genentech